Li Li, Liu Zhulin, Han Rui, Li Lin, Wang Mengyao, Huang Depei, He Yong
Department of Respiratory Disease, Daping Hospital, Army Medical University, Chongqing, P.R. China.
The Medical Department, 3D Medicines Inc., Shanghai, P.R. China.
Clin Med Insights Oncol. 2020 Aug 25;14:1179554920947335. doi: 10.1177/1179554920947335. eCollection 2020.
About one-third of nonsmall cell lung cancer (NSCLC) patients develop brain metastases (BM). However, there is an unmet need for early diagnosis and treatment of BM. The precise mechanism for BM is still unknown. However, the genetic heterogeneity between primary tumor and paired BM indicates that sampling from the primary tumor may not be able to fully represent the mutational status in metastases. In this study, the genetic heterogeneity of primary lung adenocarcinoma and paired BM was analyzed.
A total of 11 paired samples of primary tumors and BM from lung cancer patients were included, in which 7 paired samples of patients were finally analyzed. Samples were sequenced by whole-exome sequencing (WES) to investigate the common and unique mutations in the primary tumors and BM, and the similarities and differences in copy number variation (CNV).
The consistency of gene mutation between primary lung adenocarcinoma and paired BM was 33% to 86%. FAM129C and ADAMTSs specifically mutated in BM, along with NKX2-1 high amplification and SAMD2/4 copy number deletion.
The consistency of gene mutation between primary lung adenocarcinoma and corresponding BM is relatively high, while the individual differences were significant. FAM129C and ADAMTSs mutations and high amplification of NKX2-1 may be related to BM of lung cancer. The loss of copy number of SAMD2/4 may be a potential therapeutic target for BM from lung adenocarcinoma.
约三分之一的非小细胞肺癌(NSCLC)患者会发生脑转移(BM)。然而,BM的早期诊断和治疗仍存在未满足的需求。BM的确切机制尚不清楚。然而,原发性肿瘤与配对的BM之间的基因异质性表明,从原发性肿瘤取样可能无法完全代表转移灶中的突变状态。在本研究中,分析了原发性肺腺癌与配对BM的基因异质性。
共纳入11例肺癌患者的原发性肿瘤和BM配对样本,最终分析了其中7例患者的配对样本。通过全外显子组测序(WES)对样本进行测序,以研究原发性肿瘤和BM中的共同和独特突变,以及拷贝数变异(CNV)的异同。
原发性肺腺癌与配对BM之间的基因突变一致性为33%至86%。FAM129C和ADAMTSs在BM中特异性突变,同时伴有NKX2-1高扩增和SAMD2/4拷贝数缺失。
原发性肺腺癌与相应BM之间的基因突变一致性相对较高,但个体差异显著。FAM129C和ADAMTSs突变以及NKX2-1的高扩增可能与肺癌的BM有关。SAMD2/4拷贝数的缺失可能是肺腺癌BM的潜在治疗靶点。